Trial Profile
A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Combretastatin A1 phosphate (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 14 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
- 14 Jan 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record
- 09 Feb 2015 Time frame for primary endpoint changed from 3 years to 28 days as reported by ClinicalTrials.gov record.